Nanovi Secures EUR 2.7 M to Market BioXmark®

Nanovi, specialized in the development of advanced biomaterials for use in the radiotherapy of cancer, today announced it secured €2.7M from current investors to bring BioXmark® technology to the market. BioXmark™ is a novel injectable liquid tissue marker which improves the accuracy and quality of radiation therapy. It can easily be implemented in today’s routines

Kræftbehandling handler om præcision (external coverage in Danish)

Kræftpatienter har udsigt til en mere effektiv strålebehandling med en ny teknologi, en markør I nanostørrelse, der afslører tumorers nøjagtige placering i kroppen. Read more

Nanovi among the most promising spin-outs (external coverage).

An American journal has highlighted Nanovi—the DTU spin-out—as one of the most promising players in the field of radiation therapy. In March 2014, Nanovi was selected and presented as one of the most promising start-up enterprises focusing on radiation therapy for cancer. The profile was published in the American journal Start-up, which specializes in in-depth

Injectable liquid tissue marker for improved radiation precision (external coverage: start-up):

The unavailability of a good fiducial marker for pre-treatment image planning and subsequent image-guided radiotherapy is currently a major obstacle to enhancing radiotherapy standards. Copenhagen, Denmark-based start-up Nanovi ApS has developed an injectable, liquid, biomaterials-based tissue marker that promises to improve accuracy in IGRT of several types of cancer, including lung cancer. Read more

Nanovi Secures Funding for BioXmark® injectable Tissue Liquid Marked in Radiotherapy

Nanovi is developing products based on advanced biomaterials for use in the treatment of cancer. Nanovi’s first product (BioXmark™) is an injectable tissue liquid marker, used to improve accuracy in the radiation treatment of patients with cancer. BioXmark™ has the potential to increase radiotherapy quality with minimal changes in today’s procedures and equipment. It will